Matthew D Cheung1,2,3, Elise N Erman1,2,3, Shanrun Liu4, Nathaniel B Erdmann5, Gelare Ghajar-Rahimi1,2,3, Kyle H Moore1,2,3, Jeffrey C Edberg4, James F George2,3, Anupam Agarwal1,2. 1. Division of Nephrology, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama. 2. Department of Medicine, Nephrology Research and Training Center, University of Alabama at Birmingham, Birmingham, Alabama. 3. Division of Cardiothoracic Surgery, Department of Surgery, University of Alabama at Birmingham, Birmingham, Alabama. 4. Division of Clinical Immunology and Rheumatology, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama. 5. Division of Infectious Diseases, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama.
Abstract
Background: AKI is a common sequela of infection with SARS-CoV-2 and contributes to the severity and mortality from COVID-19. Here, we tested the hypothesis that kidney alterations induced by COVID-19-associated AKI could be detected in cells collected from urine. Methods: We performed single-cell RNA sequencing (scRNAseq) on cells recovered from the urine of eight hospitalized patients with COVID-19 with (n=5) or without AKI (n=3) as well as four patients with non-COVID-19 AKI (n=4) to assess differences in cellular composition and gene expression during AKI. Results: Analysis of 30,076 cells revealed a diverse array of cell types, most of which were kidney, urothelial, and immune cells. Pathway analysis of tubular cells from patients with AKI showed enrichment of transcripts associated with damage-related pathways compared with those without AKI. ACE2 and TMPRSS2 expression was highest in urothelial cells among cell types recovered. Notably, in one patient, we detected SARS-CoV-2 viral RNA in urothelial cells. These same cells were enriched for transcripts associated with antiviral and anti-inflammatory pathways. Conclusions: We successfully performed scRNAseq on urinary sediment from hospitalized patients with COVID-19 to noninvasively study cellular alterations associated with AKI and established a dataset that includes both injured and uninjured kidney cells. Additionally, we provide preliminary evidence of direct infection of urinary bladder cells by SARS-CoV-2. The urinary sediment contains a wealth of information and is a useful resource for studying the pathophysiology and cellular alterations that occur in kidney diseases.
Background: AKI is a common sequela of infection with SARS-CoV-2 and contributes to the severity and mortality from COVID-19. Here, we tested the hypothesis that kidney alterations induced by COVID-19-associated AKI could be detected in cells collected from urine. Methods: We performed single-cell RNA sequencing (scRNAseq) on cells recovered from the urine of eight hospitalized patients with COVID-19 with (n=5) or without AKI (n=3) as well as four patients with non-COVID-19 AKI (n=4) to assess differences in cellular composition and gene expression during AKI. Results: Analysis of 30,076 cells revealed a diverse array of cell types, most of which were kidney, urothelial, and immune cells. Pathway analysis of tubular cells from patients with AKI showed enrichment of transcripts associated with damage-related pathways compared with those without AKI. ACE2 and TMPRSS2 expression was highest in urothelial cells among cell types recovered. Notably, in one patient, we detected SARS-CoV-2 viral RNA in urothelial cells. These same cells were enriched for transcripts associated with antiviral and anti-inflammatory pathways. Conclusions: We successfully performed scRNAseq on urinary sediment from hospitalized patients with COVID-19 to noninvasively study cellular alterations associated with AKI and established a dataset that includes both injured and uninjured kidney cells. Additionally, we provide preliminary evidence of direct infection of urinary bladder cells by SARS-CoV-2. The urinary sediment contains a wealth of information and is a useful resource for studying the pathophysiology and cellular alterations that occur in kidney diseases.
Authors: Victor G Puelles; Marc Lütgehetmann; Maja T Lindenmeyer; Jan P Sperhake; Milagros N Wong; Lena Allweiss; Silvia Chilla; Axel Heinemann; Nicola Wanner; Shuya Liu; Fabian Braun; Shun Lu; Susanne Pfefferle; Ann S Schröder; Carolin Edler; Oliver Gross; Markus Glatzel; Dominic Wichmann; Thorsten Wiech; Stefan Kluge; Klaus Pueschel; Martin Aepfelbacher; Tobias B Huber Journal: N Engl J Med Date: 2020-05-13 Impact factor: 91.245
Authors: Nathan H Raines; Matthew D Cheung; Landon S Wilson; Jeffrey C Edberg; Nathaniel B Erdmann; Alec A Schmaier; Taylor F Berryhill; Zachary Manickas-Hill; Jonathan Z Li; Xu G Yu; Anupam Agarwal; Stephen Barnes; Samir M Parikh Journal: Kidney Int Rep Date: 2021-09-14
Authors: Laura E Lamb; Nivedita Dhar; Ryan Timar; Melissa Wills; Sorabh Dhar; Michael B Chancellor Journal: Med Hypotheses Date: 2020-11-05 Impact factor: 1.538
Authors: John T Killian; Julie A Houp; Greer A Burkholder; Salomon A Roman Soto; A Cozette Killian; Song C Ong; Nathaniel B Erdmann; Paul A Goepfert; Vera Hauptfeld-Dolejsek; Sixto M Leal; Esther Zumaquero; Anoma Nellore; Gaurav Agarwal; Clifton E Kew; Babak J Orandi; Jayme E Locke; Paige M Porrett; Emily B Levitan; Vineeta Kumar; Frances E Lund Journal: Transpl Int Date: 2022-07-19 Impact factor: 3.842